Login to Your Account

Therapy Targets Coronary Artery Disease

Cardium Launches Phase III Trial of Gene Therapy Generx

By Marie Powers
Staff Writer

Wednesday, March 21, 2012
Cardium Therapeutics Inc. initiated a Phase III registration study of lead product candidate Generx (alferminogene tadenovec, Ad5FGF-4) in myocardial ischemia.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription